drugset / Trial / NCT01419717
Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer
NaSingle-groupOpen-labelTreatment
Summary
This trial will facilitate access to denosumab for adults with advanced cancer who have participated in a denosumab phase 3 study until denosumab is approved and available for sale.
Timeline
- Start
- 2011-11-22
- Primary completion
- 2018-08-10
- Completion
- 2018-08-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Denosumab | Monoclonal antibody | 120 mg | Subcutaneous |
Indications
No indication recorded.